Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Otsuka Beijing Research Institute Zhejiang Otsuka Pharmaceutical Co., Ltd. |
---|---|
Information provided by: | Otsuka Beijing Research Institute |
ClinicalTrials.gov Identifier: | NCT00202020 |
The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003. From the end of May 2004 to the end of Dec. 2004, 720 patients with previous cerebral infarction(see the inclusion criteria) were enrolled in to the study and received one of the two treatment regimens, Cilostazol or Aspirin, the ratio of patient number of each group is 1:1. For each patient, the chance of entering either of these two groups is the same. The treatment will continue till the end of 2005. During the treatment period, patients will be observed concerning some certain events, mainly reoccurrence of stroke. If the patient experiences reoccurrence of stroke, or other event that the doctors think it is not appropriate to continue the study medication, this patient would stop the treatment. Patients were also required to take MRI head scan before entering the study and on completion of the treatment.
Condition | Intervention | Phase |
---|---|---|
Cerebral Infarction |
Drug: Cilostazol 200mg/day Oral Drug: Aspirin 100mg/day Oral |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial |
Estimated Enrollment: | 720 |
Study Start Date: | May 2004 |
Estimated Study Completion Date: | January 2006 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. Patients who had cerebral infarction within 6 months and 1 month before entry 2. Within a few days of the onset of cerebral infarction onset, CT or MRI showed evidence of infarction that could be responsible for this stroke onset 3. A modified ranking scale of less than 4 4. Aged 18~75 5. Consent of the patients or their legal guardians
-
Exclusion Criteria:
Judged to be inappropriate to enter the study by investigators. -
-
China | |
1st affiliated hospital, Peking University | |
Beijing, China | |
Huashan Hospital Shanghai Fudan University | |
Shanghai, China | |
General Hospital of Beijing Military Area of PLA | |
Beijing, China | |
Renmin Hospital, Peking University | |
Beijing, China | |
Renji Hospital, Shanghai 2nd medical university | |
Shanghai, China | |
General Hospital, Tianjin Medical University | |
Tianjin, China | |
3rd affiliated hospital, Peking University | |
Beijing, China | |
China, Guangdong | |
1st affiliated hospital, Guangzhou Zhongshan University | |
Guangzhou, Guangdong, China | |
2nd affiliated hospital, Guangzhou medical college | |
Guangzhou, Guangdong, China | |
China, Jilin | |
1st affiliated Jilin University | |
Changchun, Jilin, China | |
China, Shanxi | |
1st affiliated hospital, Xi'an Jiatong University | |
Xi'an, Shanxi, China | |
China, Zhejiang | |
2nd affiliated hospital, Zhejiang University | |
Hangzhou, Zhejiang, China |
Principal Investigator: | Yi N Huang, Professor | Peking University First Hospital |
Study ID Numbers: | OBRI0001 |
Study First Received: | September 12, 2005 |
Last Updated: | March 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00202020 History of Changes |
Health Authority: | China: State Food and Drug Administration |
Cerebral infarction Prevention Cilostazol |
Aspirin Stroke Clinical trial |
Anti-Inflammatory Agents Vasodilator Agents Cerebral Infarction Fibrinolytic Agents Brain Diseases Neuroprotective Agents Cerebrovascular Disorders Necrosis Fibrin Modulating Agents Aspirin Brain Ischemia Anti-Inflammatory Agents, Non-Steroidal Analgesics Cilostazol Stroke |
Cyclooxygenase Inhibitors Vascular Diseases Anti-Asthmatic Agents Central Nervous System Diseases Ischemia Cardiovascular Agents Phosphodiesterase Inhibitors Analgesics, Non-Narcotic Platelet Aggregation Inhibitors Brain Infarction Peripheral Nervous System Agents Infarction Antirheumatic Agents Bronchodilator Agents |
Anti-Inflammatory Agents Respiratory System Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Cerebral Infarction Hematologic Agents Physiological Effects of Drugs Fibrinolytic Agents Brain Diseases Neuroprotective Agents Cerebrovascular Disorders Fibrin Modulating Agents Necrosis Pathologic Processes Aspirin |
Sensory System Agents Therapeutic Uses Brain Ischemia Cardiovascular Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Cilostazol Cyclooxygenase Inhibitors Nervous System Diseases Stroke Vascular Diseases Anti-Asthmatic Agents Central Nervous System Diseases Enzyme Inhibitors Cardiovascular Agents |